15 citations
,
August 2022 in “The Application of Clinical Genetics” ABCD1 gene mutations cause adrenomyeloneuropathy, leading to symptoms like limb weakness and spasticity, with management focusing on rehabilitation and spasticity treatment.
6 citations
,
April 2020 in “Cureus” A woman with both TLE and SLE improved with hydroxychloroquine treatment.
June 2010 in “Melanoma research” LDE225 is a promising skin-applied treatment for basal cell carcinoma with good skin penetration and effectiveness.
Anifrolumab improves quality of life and reduces steroid use in lupus patients.
January 2023 in “Toxicological Research” September 2025 in “Bioengineering” The framework helps predict adverse effects of blood thinners, improving drug selection for atrial fibrillation.
December 2019 in “University of Malaya Students Repository” Mimosine from Leucaena leucocephala can enhance biodiesel stability.
March 2010 in “European Urology Supplements” 16 citations
,
November 2018 in “Medicinal Chemistry” The compound GD-23 may reduce anxiety like diazepam by targeting the TSPO receptor.
April 2014 in “The FASEB Journal” Testosterone reduces knee movement, while flutamide and finasteride increase it.
24 citations
,
December 2012 in “Behavioural Brain Research” Changing Allopregnanolone levels in newborns affects adult behavior and anxiety.
1 citations
,
September 2021 in “Dermatologic Therapy” Botulinum toxin injections effectively relieve pain from cutaneous leiomyomas.
3 citations
,
September 2024 in “BMC Oral Health” Low-level laser therapy reduces orthodontic relapse in rats, but fulvic acids do not.
3 citations
,
May 2017 in “Bioorganic & medicinal chemistry letters” New compounds were made that are promising for prostate cancer therapy.
20 citations
,
August 2017 in “Drug testing and analysis” Drugs localize differently in hair strands based on their properties.
May 2024 in “News Digital Object Group” 70 citations
,
February 2018 in “Seminars in Arthritis and Rheumatism” Belimumab reduces disease activity, steroid use, and flares in lupus patients.
10 citations
,
August 1998 in “Journal of Investigative Dermatology” The compounds tested could potentially treat hair loss and alopecia.
August 2002 in “Analytical Sciences” The document concludes that a compound with potential for treating prostate cancer and hair loss was successfully made and its detailed structure was confirmed.
September 2012 in “DOAJ (DOAJ: Directory of Open Access Journals)” D-004 shows moderate antidepressant effects but is less effective than Sertraline and Imipramine.
1 citations
,
June 2022 in “JCRPE” Metreleptin treatment significantly improved metabolic health in a boy with congenital generalized lipodystrophy.
24 citations
,
July 2019 in “Cochrane library” Some treatments like methotrexate with prednisone might help juvenile morphea, but more research is needed to confirm.
January 2017 in “Anais do 5º Encontro Brasileiro para Inovação Terapêutica” The oils showed potential to kill certain cancer cells, especially from Dysphania ambrosioides.
8 citations
,
July 2003 in “Journal of the American Geriatrics Society” Venlafaxine may cause paranoid delusions in some patients.
29 citations
,
July 2012 in “Fertility and Sterility” Low and ultralow doses of flutamide can cause liver damage in young women with high androgen levels, regardless of dose or birth control use, with higher risk for those with higher BMI and liver enzyme levels before treatment.
MFN2 mutations cause mitochondrial problems, leading to more upper body fat and lower leptin levels.
19 citations
,
April 2017 in “Synapse” Blocking allopregnanolone production in mice makes them more anxious after stress, but this can be reversed with a drug that mimics allopregnanolone.
10 citations
,
February 2009 in “European urology. Supplement” Treatment for benign prostatic hyperplasia involves drugs that either quickly relieve symptoms or reduce prostate size, with a combination offering more benefits but more side effects.
52 citations
,
April 2002 in “Brain Research” Lower allopregnanolone levels increase stress-related dopamine release in the brain.